Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 14, 2014; 20(34): 12322-12329
Published online Sep 14, 2014. doi: 10.3748/wjg.v20.i34.12322
Table 1 Characteristics of the included articles n (%)
Ref.YearCountrySettingNumber of patientsNSAID dose and durationPEP in NSAID groupPEP in placebo group
Murray et al[18]2003ScotlandSingle center220Suppository, 100 mg after ERCP7 (6.4)17 (15.5)
Cheon et al[17]2007United StatesSingle center207Oral, 50 mg before and after ERCP17 (16.2)17 (16.7)
Sotoudehmanesh et al[9]2007IranSingle center480Suppository, 100 mg before ERCP7 (2.8)15 (6.1)
Montaño Loza et al[19]2007MexicoSingle center150Suppository, 100 mg before ERCP4 (5.3)-
Khoshbaten et al[16]2008IranSingle center100Suppository, 100 mg after ERCP2 (4.0)13 (26.0)
Senol et al[15]2009TurkeySingle center80Infusion, 75 mg after ERCP3 (7.5)7 (17.5)
Elmunzer et al[14]2012United StatesMulti-center602Suppository, 50 mg after ERCP27 (9.1)52 (25.1)
Otsuka et al[5]2012JapanSingle center104Suppository, 50 mg before ERCP2 (3.9)10 (18.9)
Table 2 Quality assessments of the included studies
Ref.Random sequence generationAllocation concealmentBlinding of participants and personnelBlinding of outcomeIncomplete outcome dataSelective reporting
Murray et al[18]Mentioned, not describedDescribedMentioned, not describedNot mentionedCompletedNot mentioned
Cheon et al[17]DescribedDescribedMentioned, not describedMentioned, not describedCompletedNot mentioned
Sotoudehmanesh et al[9]Mentioned, not describedMentioned, not describedMentioned, not describedDescribedCompletedNot mentioned
Montaño Loza et al[19]Mentioned, not describedNot mentionedNot mentionedNot mentionedCompletedNot mentioned
Khoshbaten et al[16]Mentioned, not describedNot mentionedMentioned, not describedNot mentionedCompletedNot mentioned
Senol et al[15]Mentioned, not describedNot mentionedNot mentionedNot, mentionedCompletedNot mentioned
Elmunzer et al[14]Mentioned, not describedNot mentionedDescribedDescribedCompletedNot mentioned
Otsuka et al[5]Mentioned, not describedMentioned, not describedNot mentionedNot mentionedCompletedNot mentioned
Table 3 Subgroup and sensitivity analyses to evaluate the effect of nonsteroidal anti-inflammatory drug administration on post-endoscopic retrograde cholangiopancreatography pancreatitis prevention
TrialsSubgroup (n)RR (95%CI)ZP valueHeterogeneity
χ2PI2(%)
The overall effect of NSAIDs on PEP
All forms8 studies (1883)0.43 (0.33-0.56)6.18< 0.000110.680.1534
Different administration routes
Suppository6 studies (1596)0.35 (0.26-0.48)6.47< 0.00012.720.740
Oral1 study (207)0.97 (0.53-1.80)0.090.93---
Infusion1 study (80)0.43 (0.12-1.54)1.300.19---
Different definitions of PEP
The same criteria6 studies (1563)0.46 (0.34-0.61)5.24< 0.00018.380.1440
Others2 studies (320)0.30 (0.15-0.61)3.310.0011.380.2427
Different research settings
Single center7 studies (1381)0.47 (0.33-0.66)4.27< 0.00019.450.1537
Multi-center1 study (502)0.36 (0.24-0.56)4.61< 0.0001---
Different dosages
100 mg4 studies (990)0.36 (0.22-0.59)4.05< 0.00012.150.540
75 mg1 study (80)0.43 (0.12-1.54)1.300.19---
50 mg3 studies (813)0.47 (0.33-0.65)4.49< 0.00017.910.0275